0
Signin
countryflagCA

888-969-2592

RY 151.2 -0.6636% TD 80.12 0.9577% SHOP 83.0 1.3802% CNR 158.42 -0.9751% ENB 50.51 0.0198% CP 113.01 0.9108% BMO 119.55 0.3357% TRI 227.18 0.6334% CNQ 47.185 -0.851% BN 64.45 1.7524% ATD 82.17 -0.8208% CSU 4335.0 0.7153% BNS 62.975 -0.3402% CM 69.78 0.7508% SU 53.02 0.9136% TRP 57.81 1.1018% NGT 63.51 -3.5535% WCN 241.16 -2.9029% MFC 35.73 0.7614% BCE 45.805 0.0546%

Elixxer Ltd

Healthcare CA ELXR

1.15CAD
-(-%)

Last update at 2024-07-22T13:30:00Z

Day Range

1.151.15
LowHigh

52 Week Range

1.151.15
LowHigh

Fundamentals

  • Previous Close 1.15
  • Market Cap13.05M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.50401M
  • Revenue TTM0.00002M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.04M
  • Diluted EPS TTM-1.02

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.09019M -3.66271M -9.78346M - -16.53000M
Minority interest - - - - -
Net income -14.17232M -3.66271M -9.78346M - -16.53000M
Selling general administrative 2.22M 2.07M 3.29M - 13.30M
Selling and marketing expenses - - - - -
Gross profit - - - - -10.01339M
Reconciled depreciation 0.00000M 0.00196M 0.00197M - 0.00033M
Ebit - -2.09722M -5.44451M -8.94654M -13.51795M
Ebitda -11.63913M -1.93687M -7.71789M - -15.65639M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -2.42384M -2.09722M -5.44451M - -13.18304M
Other operating expenses - - - - -
Interest expense 2.45M 1.72M 2.06M 0.00000M 0.87M
Tax provision - - - - -
Interest income 0.08M 0.04M 1.09M - 0.17M
Net interest income -3.06393M -1.68147M -1.61007M - -0.82291M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.08M 0.00000M 0.02M - 0.17M
Total operating expenses 2.51M 2.10M 5.46M - 13.36M
Cost of revenue - - - - 10.36M
Total other income expense net -8.60242M 0.12M -2.72889M - -2.52405M
Discontinued operations - - - - -
Net income from continuing ops -14.09019M -3.66271M -9.78346M - -16.53000M
Net income applicable to common shares -14.17232M -3.66271M -9.78346M -18.94490M -16.53000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5.37M 16.84M 20.81M - 20.74M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 10.95M 8.45M 16.06M - 3.06M
Total stockholder equity -5.58488M 8.38M 4.76M - 17.67M
Deferred long term liab - - - - -
Other current liab - - - 0.00315M 0.19M
Common stock - 53.26M 49.57M 48.96M 32.34M
Capital stock 53.44M 53.26M 49.57M - 32.34M
Retained earnings -80.50239M -66.33007M -62.66736M -52.88390M -29.01391M
Other liab - - - - -
Good will - - - - -
Other assets - 0.32M 0.36M 0.40M 2.70M
Cash 0.07M 0.30M 2.10M - 6.57M
Cash and equivalents - - - - -
Total current liabilities 7.34M 8.45M 16.06M 10.78M 3.06M
Current deferred revenue - - - - -
Net debt 7.96M 6.24M 10.99M - -
Short term debt - - - - -
Short long term debt 4.41M 6.54M 13.09M - 2.53M
Short long term debt total - - - - -
Other stockholder equity 4.04M 4.79M 4.33M 4.38M 4.35M
Property plant equipment - - 0.00555M 0.00751M 0.00997M
Total current assets 2.53M 13.70M 2.33M 2.89M 6.78M
Long term investments 2.84M 0.69M 15.99M - 7.84M
Net tangible assets - 8.38M 4.76M 13.18M 17.67M
Short term investments 2.41M 13.28M - - 0.00000M
Net receivables - 0.11M 0.22M 1.25M 0.21M
Long term debt 3.61M - - - -
Inventory - - - - -
Accounts payable 2.93M 1.89M 1.54M 2.29M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.76M
Deferred long term asset charges - - - - -
Non current assets total 2.84M 3.14M 18.49M - 13.96M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 2.32M 2.19M 1.06M -3.71823M -4.82101M
Change to liabilities 1.02M -1.00201M 0.54M 1.64M -0.02715M
Total cashflows from investing activities - 2.19M 1.06M -12.97768M -9.25895M
Net borrowings 1.04M 0.16M 2.74M 4.08M 2.62M
Total cash from financing activities 0.46M 0.03M 3.13M 14.79M 18.32M
Change to operating activities - - - 1.16M 1.16M
Net income -14.17232M -3.66271M -9.78346M -18.94490M -16.53000M
Change in cash -0.23634M -1.80099M 1.18M -4.51337M 4.55M
Begin period cash flow 0.30M 2.10M 0.92M 6.57M 2.02M
End period cash flow 0.07M 0.30M 2.10M 0.92M 6.57M
Total cash from operating activities -3.02085M -4.01901M -3.01302M -6.33022M -4.50692M
Issuance of capital stock - 0.00000M 0.40M - 11.79M
Depreciation 0.00000M 0.00196M 0.00197M 0.00197M 0.00033M
Other cashflows from investing activities - - - -5.31689M -1.56810M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.11M 0.17M -0.12246M -0.02212M -0.15962M
Sale purchase of stock -0.58159M -0.12929M - - -
Other cashflows from financing activities - - 0.26M 0.82M -0.91895M
Change to netincome - 0.48M 6.35M 10.99M 12.21M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.13M -0.83567M 0.42M - -0.28403M
Stock based compensation 0.00000M 0.00079M 0.41M - -
Other non cash items 1.11M 0.54M 9.50M - 0.67M
Free cash flow -3.02085M -4.01901M -3.01302M - -4.61448M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ELXR
Elixxer Ltd		 - -% 1.15 - - 767773.80 2.67 113.53 -2.6271
RX
Biosyent Inc.		 -0.19 1.88% 9.91 16.47 16.26 3.21 2.88 2.32 8.03
LOVE
Cannara Biotech Inc		 -0.04 6.67% 0.56 10.00 - 1.26 0.90 1.98 7.20
DB
Decibel Cannabis Company Inc		 - -% 0.06 - 3.38 0.48 1.17 0.87 39.48
LSL
LSL Pharma Group Inc.		 -0.005 1.04% 0.47 - - 4.65 4.23 6.13 -14.2493

Reports Covered

Stock Research & News

View All

Profile

Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.

Elixxer Ltd

100 Boulevard Rene- Levesque Ouest, Montreal, QC, Canada, H5B 4N4

Key Executives

Name Title Year Born
Mr. Ferras Zalt Chairman & Interim CEO 1963
Ms. Kym No C.M.A., CPA Corp. Controller & Interim CFO NA
Mr. Guy Charette L.L.B., LL.B. Legal Council 1954
Ms. Jeanne van Wyk VP of Communications NA
Mr. Daniel Lubienietzky VP of Corp. Devel. NA
Mr. Richard Widmann EVP of Commercial 1968
Mr. Michael Kozub Corp. Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.